Data from Tango slide deck of PRMT5inh plus KRASinh (Daraxonrasib, left and Zoldonrasib, right) in 2nd/3rd line #PancreaticCancer ir.tangotx.com/static-files/… In this recent study (Boston Gene), ~20% of pancreatic cancers have KRAS mut plus MTAP co-deletion. aacrjournals.org/clincancerr…

Technically MTAP loss and the resulting therapeutic vulnerability created is an example of “collateral lethality”. statnews.com/2026/06/11/synt… A term first proposed by @RonDePinho nature.com/articles/nature21… However there may be an element of synthetic lethality here as well…(1/2)

Very nice resource paper in @Cancer_Cell that enables correlation of cell type specific expression data with survival in #PancreaticCancer. cell.com/cancer-cell/fulltex… Takes TCGA type datasets based on bulk RNA to the next level. Interactive web tool (ctPANDA) allows facile queries.

The US government, citing national security authorities, has issued an export control directive to suspend all access to Fable 5 and Mythos 5 by any foreign national, whether inside or outside the United States, including foreign national Anthropic employees. The net effect of this order is that we must abruptly disable Fable 5 and Mythos 5 for all our customers to ensure compliance. Access to all other Claude models is not affected. We apologize for this disruption to our customers. We believe this is a misunderstanding and are working to restore access as soon as possible. Read our full statement: anthropic.com/news/fable-myt…

For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @EvidenceOpen and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine nature.com/articles/s41591-0…

🆕@JCOPO_ASCO 💡Such a beautiful story of real world🌎 precision medicine. Meet➡️#ERRFI1🎯 📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN 👇🏽Patient in paper, I took off hospice to give Erlotinib💊. @OncoAlert 🔗ascopubs.org/doi/10.1200/PO-…

The first shipments of Daraxonrasib have arrived! -given through the @RevMedicines EAP program -authorized by the @FDA_Drug_Info -welcomed by oncologists -and appreciated by PDAC patients & families Dr. @steveleeyc knows exactly when to bring his daughter into work for a historic moment! A KRAS moment that will bring hope (and tears) to patients across the US. @letswinpc @lustgartenfdn @kevansf @DavidHongMD @GarridoLagunaMD @Aiims1742

First-in-human KRAS G12D inhibitor DN022150 shows promising early activity in heavily pretreated solid tumors: no DLTs, manageable safety, ~30–38% ORR and high disease control with widespread tumor shrinkage. #ASCO26

🟨Rilvegostomig Gem-Cis in 1L of advanced BTC #ASCO26 ✅mOS: 16.8 mo ⏰Looking forward to results of phase III Artemide studies #cancer #oncology #MedX #biliary #cholangiocarcinoma @curecc @PrecisionBTCnet @OncoAlert @AstraZeneca

Aumentare il costo di #sigarette e prodotti da fumo per contrastare il #tabagismo funziona: lo dicono le altre esperienze europee. Aderisci alla campagna #5eurocontroilfumo: firmereferendum.giustizia.it… @AIRC_it @Fondaz_Veronesi

Now out online in @Cancer_Cell . Fun writing this with @sundar__raghav and talented student Luke Tillman and other. Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation: Cancer Cell cell.com/cancer-cell/fulltex…

Today we all lost our jobs..... Three Nature papers showing that scientists in the conventional sense are obsolete At least read the first one.... the AI replaced all things that the scientist does .... nature.com/articles/s41586-0…

Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study | JNCI: Journal of the National Cancer Institute | Oxford Academic academic.oup.com/jnci/advanc…

The “stronger IO tail effect” is from assigning patients with a lethal disease to placebo

A 🆕 30-page review in Cell maps the state of ADCs (antibody-drug conjugates) - the “magic bullet” cancer therapy first imagined in 1907. 19 approved. 260 in development. SCLC: zero. Non small cell #lungcancer has genuine options now. But the review is direct about the gaps: patient selection, toxicity management, and tumours that are simply hard to reach. cell.com/action/showPdf?pii=… #LCSM